251 results about "Acetylglucosamine" patented technology

A method for enhancing a binding activity of an antibody composition to Fcgamma receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcgamma receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.

The present invention provides a process for producing an antibody composition using a cell, which comprises using a cell into which an RNA having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is introduced; the RNA used in the production process; a DNA corresponding to the RNA; a cell in which the RNA or DNA is introduced or expressed; a process for producing the cell; and a method for suppressing the enzyme.

A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.

A method for producing lacto-N-biose I and galacto-N-biose inexpensively and conveniently is provided. The method for producing lacto-N-biose I or galacto-N-biose, characterized in that the method comprises causing: (i) a combination of a carbohydrate raw material with an enzyme that catalyzes phosphorolysis of the carbohydrate raw material to give a-glucose-1-phosphate; and (ii) a combination of an enzyme that converts α-glucose-1-phosphate to UDP-glucose and an enzyme that converts UDP-galactose to galactose-1-phosphate with their cofactors, and/or a combination of an enzyme (UDP-Gly synthase) that converts α-glucose-1-phosphate and UDP-galactose to UDP-glucose and α-galactose-1-phosphate, respectively, with its cofactor(s) to act in the presence of N-acetylglucosamine or N-acetylgalactosamine, phosphoric acid, lacto-N-biose phosphorylase (EC 2.4.1.211), and UDP-glucose-4-epimerase (EC 5.1.3.2).

The invention discloses recombinant bacillus subtitles capable of increasing the yield of acetylglucosamine and belongs to the field of genetic engineering. The recombinant bacillus subtitles is characterized in that bacillus subtitles BSGNKAP-Pxy1A-glmS-P43-GNA1 is used as the original strain, a phosphatase yqaB gene controlled by a strong constitutive promoter Pveg is integrated to the genome, and the promoter of 6-phosphate glucosamine synthase is replaced by the strong constitutive promoter Pveg to obtain genetically engineered bacillus subtitles BSGNY-Pveg-glmS-P43-GNA1 accumulating the acetylglucosamine. The recombinant bacillus subtitles has the advantages that the yield of the acetylglucosamine of a 3L fermentation tank reaches 60.5g/L, the yield of the acetylglucosamine is 0.311g/g glucose, production intensity is 0.983g/L/h, the yield of the acetylglucosamine outside the cells of the recombinant bacillus subtitles is increased, and a foundation is laid for glucosamine production using metabolic engineering modified bacillus subtitles.

The invention discloses bacillus subtilis engineering bacteria with high yield of acetylglucosamine and application of the bacillus subtilis engineering bacteria with high yield of the acetylglucosamine. Bacillus subtilisi 168 serves as an original strain. On the basis that homologous recombination knocks out acetylglucosamine glucose transporter protein coding gene (nagP), acetylglucosamine deacetylation enzyme coding gene (nag A) and acetylglucosamine deamination enzyme coding gene (nag B) are further knocked out so as to block up acetylglucosamine degradation pathway in host bacteria. In the host bacteria without the nag A and the nag B, acetylglucosamine acetylase coding gene (GNA1) from Saccharomyces cerevisiae S288C is overly expressed, an acetylglucosamine synthetic route is strengthened to produce recombination bacillus subtilis for producing acetylglucosamine, yield reaches 1.23 grams per liter, and the method is a basis for metabolic engineering to further modify bacillus subtilis to produce glucosamine.

The invention provides recombinant bacillus subtilis for synthesizing lactyl-N-neotetraose. The recombinant bacillus subtilis is integrated with lactose permease genes in a recombinant manner on bacillus subtilis 168 genome and converts plasmids which contain beta-1,3-N-glucoaminotransferase genes and beta-1,4-galactosyltransferase gene in bacillus subtilis 168. Uridine diphosphate galactose and acetylglucosamine uridine diphosphate in a metabolic pathway of the bacillus subtilis are used as precusor substances, lactose only needs to be added exogenously and is transferred into cells under theeffect of lactamase to synthesize the lactyl-N-neotetraose which is secreted to ectoenzyme. The accumulation amount of the lactyl-N-neotetraose synthesized by the recombinant bacillus subtilis reaches 1071 mg/L, and a foundation is laid for production of the lactyl-N-neotetraose through further metabolic engineering modified bacillus subtilis.

The invention discloses genetically engineered bacteria for producing N-acetylneuraminic acid as well as a construction method and application thereof. A method for preparing the genetically engineered bacteria for producing N-acetylneuraminic acid comprises the following step of: introducing genes associated with the N-acetylneuraminic acid synthesis into host bacteria so as to obtain recombinant bacteria for producing N-acetylneuraminic acid, wherein the genes associated with the N-acetylneuraminic acid synthesis are coding genes of N-acetylglucosamine and 2-isomerase and a coding gene of N-nacetylneuraminic acid aldolase. The genetically engineered bacteria for producing N-acetylneuraminic acid constructed by the invention have the following advantages that the used raw materials are relatively cheap and liable to realize industrial mass product, so that the genetically engineered bacteria play an important role in the production of N-acetylneuraminic acid in the future.

The invention provides a method for producing an orexin neuron by culturing a pluripotent stem cell or a neural progenitor cell in the presence of N-acetyl-D-mannosamine and optionally in the presence of at least one inhibitor selected from the group consisting of a Sirtuin 1 inhibitor and an O-linked β-N-acetylglucosamine transferase inhibitor. The invention also provides a therapeutic agent for narcolepsy or eating disorders, such as anorexia, containing N-acetyl-D-mannosamine, which is based on the induction of orexin neuron in vivo.

The invention belongs to the technical field of fine chemical industry and particularly relates to a method for preparing chitin oligosaccharides, chitooligosaccharides and chitosan oligosaccharides, of which the molecular weight is 50,000 or below. The method comprises the steps of firstly, dissolving chitin in a certain solvent, carrying out homogeneous degradation under acid catalysis so as to obtain the chitin oligosaccharides with certain molecular weight, and subjecting the chitin oligosaccharides to deacetylating treatment by a strong base, thereby preparing the chitooligosaccharides and the chitosan oligosaccharides. After the chitin oligosaccharides are subjected to deacetylating treatment by the strong base, the chitooligosaccharides or the chitosan oligosaccharides with the degree of deacetylation of 50% to 98% is obtained. Glycosidic bonds among acetylglucosamine are more easily degraded under the condition of acid catalysis, so that a chitin degradation reaction can be carried out under mild conditions, the yield is high, and the control on molecular weight is effectively achieved. According to the chitin oligosaccharides, chitooligosaccharides and chitosan oligosaccharides prepared by the method, the molecular weight can be continuously adjustable in the range of 1,000 to tens of thousands, the distribution of the molecular weight is relatively narrow, the product quality is high, and the production cost is reduced remarkably.

The invention discloses a method for knocking out pckA to promote synthesis of acetylglucosamine through bacillus subtilis and belongs to the field of genetic engineering. The method comprises the steps that BSGNK-PxylA-glmS-P43-GNA1 serves as original strains, phosphoenolpyruvate carboxylase (pckA) genes are knocked out through homologous recombination, the reaction that enolphosphopyruvate is converted into oxaloacetic acid in host bacterium cells is blocked, the carbon flux flowing to a tricarboxylic acid cycle is reduced, and accumulation of acetylglucosamine is promoted. In the process that a composite culture medium is used for fermentation, the acetylglucosamine yield of recombination bacillus subtilis with pckA knocked out reaches 29.27 g/L and is increased by 28.1% compared with that of control strains. The method lays a foundation for transforming bacillus subtilis to produce acetylglucosamine in metabolic engineering.

This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.

The invention discloses multipath composite neuraminic acid producing bacillus subtilis and an application thereof, and belongs to the field of genetic engineering. The expression levels of key enzymes, namely UDP-N-acetylglucosamine-2-epimerase, N-acetylglucosamine-6-phosphate isomerase, glucosamine-6-phosphoric acid-N-acetyltransferase, N-acetylglucosamine isomerase and N-acetylneuraminate synthase on genomes in three neuraminic acid synthesis paths are sequentially optimized by 10 promoters with different intensities, so that the protein synthesis pressure of enzyme expression on cells is reduced; and three neuraminic acids are further integrated into the same engineering bacillus subtilis, so that the bacillus subtilis with the increased N-acetylneuraminic acid yield is obtained, the neuraminic acid yield under the shake flask level reaches 10.4 g/L, and a foundation is laid for further increasing the NeuAc yield of the bacillus subtilis.

The invention relates to compound wine and a preparation method thereof. The compound wine comprises sodium hyaluronate, wherein the content of sodium hyaluronate in white spirit per litre is 50-300mg. The compound wine is characterized in that the average relative molecular mass of sodium hyaluronate is 5017-6689 daltons, that is sodium hyaluronate is mucopolysaccharide formed by alternately bonding 10-20 acetylglucosamine and sodium glucuronate disaccharide units. The preparation method of the compound wine employs a hydration-gelation-dissolution staged dissolution technology to allow HA (hyaluronic acid) to be capable of being dissolved in a wine base more uniformly. The compound wine is potable wine comprising new resource food sodium hyaluronate, can keep a style of white spirit, and reaches the GB/T 27588 standard on liqueur which is clear, transparent and free from precipitate and suspended matter, the turbidity is reduced simultaneously, and the long-term stable presence of sodium hyaluronate in the wine base can be ensured.

The invention discloses recombinant escherichia coli for synthesizing lactoyl N-neotetraose and a construction method and application of the recombinant escherichia coli. The recombinant escherichia coli are obtained by knocking out a beta-galactosidase lacZ gene, a glucosamine-6-phosphodeaminase nagB gene, a UDP-acetylglucosamine epitope isomerase wecB gene and a UDP-glucose dehydrogenase ugd gene in the host genome of escherichia coli and overexpressing a lactose transportase lacY gene, beta-1, 3-N-glucosaminidase lgtA gene and a beta-1, 4 galactosyltransferase lgtB gene on the genome. The yield of lactoyl-N-neotetraose synthesized by recombinant escherichia coli reaches 985 mg/L, and a foundation is laid for further metabolic engineering transformation of escherichia coli to produce lactoyl-N-neotetraose.

The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)), and benign prostatic hyperplasia is determined in the case of 30% or less.

An enzyme which transfers N-acetylgalactosamine to N-acetylglucosamine via a β1-4 linkage was isolated and the structure of its gene was explained. This led to the production of said enzyme or the like by genetic engineering techniques, the production of oligosaccharides using said enzyme, and the diagnosis of diseases on the basis of said gene or the like. The present invention uses a protein having the amino acid sequence shown in SEQ ID NO: 1, 3, 26 or 27 in the Sequence Listing or a variant of said amino acid sequence wherein one or more acids are substituted or deleted, or one or more acids are inserted or added and having the activity of transferring N-acetylgalactosamine (GalNAc) to N-acetylglucosamine serving as a substrate via a β1-4 linkage and nucleic acids encoding said protein.

The invention discloses recombinant bacillus subtilis. According to the recombinant bacillus subtilis, on the basis of the recombinant bacillus subtilis BSGNK, escherichia coli glutamine synthetase (EglnA) is overexpressed so as to obtain recombinant bacteria BSGNKN; and the recombinant bacillus subtilis BSGNK takes B. subtilis 168 delta nagP delta gamP delta gamA delta nagA delta nagB delta ldh delta pta delta glck::lox72 as a host, and the recombinant expression of glms and GNA1 is controlled by promoters PxylA and P43 respectively. The invention further discloses a method for promoting thesynthesis of acetylglucosamine by overexpressing the glutamine synthetase by virtue of the recombinant bacillus subtilis. The obtained recombinant bacillus subtilis has the advantages that the extracellular accumulation efficiency of the acetylglucosamine and the conversion efficiency of a substrate can be improved, the content of the acetylglucosamine in fermentation supernate is 7.8 g/L and is increased by 23.8% compared with the content of the acetylglucosamine of control bacteria BSGNK, a foundation is laid for further metabolic engineering modification of the bacillus subtilis for production of glucosamine, and in addition, the recombinant bacillus subtilis is simple in construction method and convenient to use and has a good application prospect.

The invention provides application of chitosan, chitosan oligosaccharide and additives thereof to preparation of an adsorbing agent for adsorbing air pollutants. The chitosan and chitosan oligosaccharide are beta-1,4 glucosidic bond connected glucosaminoglycan or acetylglucosamine, the chitosan has the polymerization degree of more than 20, and has the molecular weight of more than 5000Da; the chitosan oligosaccharide is 2-20 in polymerization degree and is 3000-5000Da in molecular weight; and the chitosan, the chitosan oligosaccharide and additives thereof are prepared into aqueous solution or glycerite with the massic volume concentration of 0.1mug/mL-2000mg/mL to be used for preparing the adsorbing agent. The prepared adsorbing agent has wide application field, can be placed in a nasal cavity in any acceptable manners, for example placing in a mask, a face mask, a headgear, a headpiece and other protective tools, and can be sprayed nearby outlets of equipment exhausting air pollutants in any acceptable manners, such as indoor equipment, factory equipment and automobiles, and has good market application value.

The present invention belongs to the field of biological engineering, and specifically discloses high-quality D-acetylglucosamine deacetylase heterologous expression and application. The amino acid sequence of the D-acetylglucosamine deacetylase is as shown in SEQNO. 1. Through enzymatic activity measurement and substrate specificity analysis, the D-acetylglucosamine deacetylase is strong in substrate specificity, and in the substrate for researches, D-acetylglucosamine (GlcNAc) and beta-bonded D-acetylglucosamine (GlcNAc) are deacetylated targetedly to generate D-glucosamine (GlcN) or beta-bonded glucosamine (GlcN). Recombinant D-acetylglucosamine deacetylase is expressed by use of genetic engineering cloning, the D-acetylglucosamine deacetylase can be strongly expressed, and high-quality D-acetylglucosamine deacetylase can be obtained.

The invention discloses application of N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 in catalytic synthesis of N-acetylmannosamine. The N-acetylmannosamine is prepared by taking the N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 as a catalyst and taking N-acetylglucosamine as a substrate. According to the invention, the N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 is used in the preparation of the N-acetylmannosamine for the first time, and favorable effect is achieved.